

Oncology Referral

Wembley:

178-190 Cambridge St, Wembley
e: bookings@envisionmi.com.au

Rockingham

2 Civic Boulevard, Rockingham
e: petrockingham@qscan.com.au

Midland

81 Yelverton Drive, Midland
e: midland@qscan.com.au

ENVISION
MEDICAL IMAGING



PROUDLY PART OF THE QSCAN GROUP

PATIENT DETAILS

Patient name:

DOB:

Phone:

Address:

Medicare:

Clinical trial / ID no.:

EXAMINATION

- ☐ PET with Whole Body Diagnostic CT (Head, Chest, Abdo, Pelvis)
- ☐ PET with localised diagnostic CT (please tick region/s)
- ☐ Head ☐ Neck ☐ Chest ☐ Abdo ☐ Pelvis ☐ Extremity
- ☐ PET with Non-Diagnostic CT (attenuation correction)

- ☐ Contrast Allergy
- ☐ Renal Impairment
- ☐ Diabetic

INDICATIONS

MBS ELIGIBLE ITEMS

- ☐ Solitary Pulmonary Nodule (61523)
- ☐ Non-Small Cell Lung cancer (61529)
- ☐ Colorectal Carcinoma (61541)
- ☐ Oesophageal/GOJ (staging) (61577)
- ☐ Melanoma (61553)
- ☐ Ovarian Carcinoma (61565)

Breast

- ☐ Staging (locally advanced) (61524)
- ☐ Suspected metastatic or recurrent (61525)

Brain

- ☐ Residual or Recurrent Malignant Tumour (61538)
- ☐ Refractory Epilepsy (61559)
- ☐ Diagnosis of Alzheimer's (61560)

Cervix Carcinoma

- ☐ Primary Staging (61571)
- ☐ Restaging (61575)

Other FDG Avid Cancers

- ☐ Staging (61612)
- ☐ Restaging (61614)

Metastatic SCC Cervical Nodes

- ☐ Unknown Primary (61610)

Head & Neck

- ☐ Staging (61598)
- ☐ Restaging (61604)

Hodgkins or NHL

- ☐ Initial staging (61620)
- ☐ First line therapy response (61622)
- ☐ Restaging (61628)
- ☐ Second line therapy response (61632)

Sarcoma (excluding GIST)

- ☐ Staging (61640)
- ☐ Restaging/Residual/Recurrent (61646)

OCTREOTATE

- ☐ Gastro entero pancreatic NET (61647)

PSMA

- ☐ Prostate staging (61563)
- ☐ Prostate recurrence (61564)
- ☐ Assessment for suitability of Lu177 PSMA therapy (61528)

MBS NON ELIGIBLE ITEMS

- ☐ Other FDG PET
- ☐ Other OCTREOTATE PET
- ☐ Other PSMA PET

MBS items must be specialist referred. MBS ineligible items will incur an out of pocket fee.

MRI

Medicare Eligible

- ☐ Brain (63001) + Contrast (63491) *unlimited*
- ☐ Liver (staging of liver mets for confirmed extra-hepatic primary malignancy) (63545) *1 per 12 months*
- ☐ Liver (Known or suspected HCC & confirmed chronic liver disease & liver function Child Pugh A or B & hepatic lesion >10mm (64546) *1 per 12 months*
- ☐ Primovist (63496)

- ☐ MRCP (63482) *3 per 12 months*
- ☐ Rectal Cancer Staging/ Restaging/ Follow-up (63476) *unlimited*
- ☐ Ca Cervix Figo ≥1B Staging Pelvis (63470) *one time only*
- ☐ Ca Cervix Figo ≥1B Staging Abdo & Pelvis (63473) *one time only*

Non Medicare Eligible

- ☐ Upper Abdomen
- ☐ Pelvis
- ☐ Other: _____

NUCLEAR MEDICINE

- ☐ Whole Body Bone Scan
- ☐ Other: _____

ULTRASOUND

- ☐ _____

CT

- ☐ _____

X-RAY

- ☐ _____

CLINICAL NOTES:

REFERRING PRACTITIONER

Name:

Provider number:

Follow up appointment:

Send copy to:

Signature:

Date:

LUNG		
Solitary Pulmonary Nodule	61523	Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
NSCLC	61529	Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.
BRAIN		
Brain	61538	FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.
Epilepsy	61559	FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.
Alzheimer's	61560	FDG PET brain for diagnosis of Alzheimer's disease if clinical evaluation (by or in consultation with a specialist) is equivocal. Not repeatable within 12 months and not more than 3 per lifetime.
GASTROINTESTINAL		
Colorectal	61541	Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.
Oesophageal/GOJ	61577	Whole body FDG PET study, performed for the staging of proven oesophageal or GOJ carcinoma, in patients considered suitable for active therapy.
GYNAECOLOGY		
Ovarian	61565	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.
Uterine Cervix	61571	Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.
Uterine Cervix	61575	Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.
HEAD & NECK		
Head & Neck	61598	Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head & neck cancer.
Head & Neck	61604	Whole body FDG PET study performed for the evaluation of patients with suspected residual head & neck cancer after definitive treatment, and who are suitable for active therapy.
MELANOMA		
Melanoma	61553	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.
SCC		
Metastatic SCC unknown primary	61610	Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
LYMPHOMA		
Lymphoma	61620	Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma.
Lymphoma	61622	Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma.
Lymphoma	61628	Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma.
Lymphoma	61632	Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma.
SARCOMA		
Bone or Soft Tissue Sarcoma	61640	Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.
Sarcoma	61646	Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.
BREAST		
PET Breast	61524	Whole body FDG PET study, performed for the staging of locally advanced (stage III) breast cancer, for a patient who is considered suitable for active therapy (R) (Anaes).
PET Breast	61525	Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R) (Anaes).
PSMA		
Prostate Staging	61563	Whole Body PSMA PET for initial staging of intermediate to high risk prostate adenocarcinoma for previously untreated patient, considered for locoregional therapy with curative intent. Once per lifetime.
Prostate Recurrence	61564	Whole body PSMA PET for restaging of recurrent prostate adenocarcinoma of patient who has undergone prior locoregional therapy and considered suitable for further locoregional therapy to determine appropriate further therapy. Twice per lifetime.
Lutetium 177	61528	Whole body PSMA PET study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor.
OTHER FDG AVID CANCERS		
Staging	61612	Whole body FDG PET study for the initial staging of cancer, for a patient who is considered suitable for active therapy, if: (a) the cancer is a typically FDG-avid cancer; and (b) there is at least 10% likelihood that a PET study result will inform a significant change in management for the patient. Applicable once per cancer diagnosis.
Restaging	61614	61614: Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent cancer in a patient who is undergoing, or is suitable for, active therapy, if the cancer is a typically FDG-avid cancer (R)
OCTREOTATE		
Gastro entero pancreatic NET	61647	Whole body 68Ga DOTA peptide PET study.